Oncternal Therapeutics, Inc. (ONCT) analyst actions
Rating and price-target actions on ONCT in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ONCT overview →
2 measured ONCT analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer | Press release | +0.26% | -1.03% | |
| Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer | Press release | — | -1.07% |
Keep exploring
More ONCT: earnings → · SEC filings → · ONCT overview →